Flibanserin for hypoactive sexual desire disorder

place in therapy

Faina Gelman, Jessica M. Atrio

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access. Testosterone, buspirone, sildenafil, bupropion, bremelanotide, as well as herbal medications (Herbal vX or Tribulus terrestris) have demonstrated some clinical benefit in women with sexual dysfunction disorders however, trials have significant design, dosing or generalizability limitations. Nonpharmaceutical cognitive behavioral therapy, mindfulness meditation, pelvic floor therapy, and clitoral stimulators are also interventions women may pursue. This manuscript will explore the clinical data regarding these therapeutic modalities so as to bring attention to this issue of female HSDD, to offer an overview of current research, and to incite providers to initiate discussion among themselves and their patients.

Original languageEnglish (US)
Pages (from-to)16-25
Number of pages10
JournalTherapeutic Advances in Chronic Disease
Volume8
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Psychological Sexual Dysfunctions
Tribulus
Buspirone
Physicians
Mindfulness
Therapeutics
Meditation
Bupropion
Pelvic Floor
Cognitive Therapy
United States Food and Drug Administration
Testosterone
flibanserin
Research

Keywords

  • female sexual interest and arousal disorders
  • flibanserin
  • hypoactive sexual desire disorder
  • libido
  • little pink pill
  • sexual dysfunction

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Flibanserin for hypoactive sexual desire disorder : place in therapy. / Gelman, Faina; Atrio, Jessica M.

In: Therapeutic Advances in Chronic Disease, Vol. 8, No. 1, 2017, p. 16-25.

Research output: Contribution to journalReview article

@article{893256d060834c5eb39d1f563d9f68a0,
title = "Flibanserin for hypoactive sexual desire disorder: place in therapy",
abstract = "The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access. Testosterone, buspirone, sildenafil, bupropion, bremelanotide, as well as herbal medications (Herbal vX or Tribulus terrestris) have demonstrated some clinical benefit in women with sexual dysfunction disorders however, trials have significant design, dosing or generalizability limitations. Nonpharmaceutical cognitive behavioral therapy, mindfulness meditation, pelvic floor therapy, and clitoral stimulators are also interventions women may pursue. This manuscript will explore the clinical data regarding these therapeutic modalities so as to bring attention to this issue of female HSDD, to offer an overview of current research, and to incite providers to initiate discussion among themselves and their patients.",
keywords = "female sexual interest and arousal disorders, flibanserin, hypoactive sexual desire disorder, libido, little pink pill, sexual dysfunction",
author = "Faina Gelman and Atrio, {Jessica M.}",
year = "2017",
doi = "10.1177/2040622316679933",
language = "English (US)",
volume = "8",
pages = "16--25",
journal = "Therapeutic Advances in Chronic Disease",
issn = "2040-6223",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Flibanserin for hypoactive sexual desire disorder

T2 - place in therapy

AU - Gelman, Faina

AU - Atrio, Jessica M.

PY - 2017

Y1 - 2017

N2 - The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access. Testosterone, buspirone, sildenafil, bupropion, bremelanotide, as well as herbal medications (Herbal vX or Tribulus terrestris) have demonstrated some clinical benefit in women with sexual dysfunction disorders however, trials have significant design, dosing or generalizability limitations. Nonpharmaceutical cognitive behavioral therapy, mindfulness meditation, pelvic floor therapy, and clitoral stimulators are also interventions women may pursue. This manuscript will explore the clinical data regarding these therapeutic modalities so as to bring attention to this issue of female HSDD, to offer an overview of current research, and to incite providers to initiate discussion among themselves and their patients.

AB - The pathophysiology, diagnosis and treatment of female sexual interest in pre- and post-menopausal women present a complex arena for patients and physicians to navigate. Flibanserin was the first pharmacologic treatment, approved by the United States Food and Drug Administration in August 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. Side effects, contraindications and lack of approval in postmenopausal women are all limitations, as are issues surrounding patient and physician knowledge and access. Testosterone, buspirone, sildenafil, bupropion, bremelanotide, as well as herbal medications (Herbal vX or Tribulus terrestris) have demonstrated some clinical benefit in women with sexual dysfunction disorders however, trials have significant design, dosing or generalizability limitations. Nonpharmaceutical cognitive behavioral therapy, mindfulness meditation, pelvic floor therapy, and clitoral stimulators are also interventions women may pursue. This manuscript will explore the clinical data regarding these therapeutic modalities so as to bring attention to this issue of female HSDD, to offer an overview of current research, and to incite providers to initiate discussion among themselves and their patients.

KW - female sexual interest and arousal disorders

KW - flibanserin

KW - hypoactive sexual desire disorder

KW - libido

KW - little pink pill

KW - sexual dysfunction

UR - http://www.scopus.com/inward/record.url?scp=85011580062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011580062&partnerID=8YFLogxK

U2 - 10.1177/2040622316679933

DO - 10.1177/2040622316679933

M3 - Review article

VL - 8

SP - 16

EP - 25

JO - Therapeutic Advances in Chronic Disease

JF - Therapeutic Advances in Chronic Disease

SN - 2040-6223

IS - 1

ER -